TY - JOUR
T1 - Predictors of liver cirrhosis and hepatocellular carcinoma among perioperative survivors of the Fontan operation
AU - Inuzuka, Ryo
AU - Nii, Masaki
AU - Inai, Kei
AU - Shimada, Eriko
AU - Shinohara, Tokuko
AU - Kogiso, Tomomi
AU - Ono, Hiroshi
AU - Otsuki, Shin Ichi
AU - Kurita, Yoshihiko
AU - Takeda, Atsuhito
AU - Hirono, Keiichi
AU - Takei, Kota
AU - Yasukohchi, Satoshi
AU - Yoshikawa, Tadahiro
AU - Furutani, Yoshiyuki
AU - Shinozaki, Tomohiro
AU - Matsuyama, Yutaka
AU - Senzaki, Hideaki
AU - Tokushige, Katsutoshi
AU - Nakanishi, Toshio
N1 - Funding Information:
This study was conducted as a programme of the Japan Agency for Medical Research and Development. This research was supported by AMED (grant number: JP16ek0109146) and the MHLW Health and Labour Sciences Research Grants for Research on Intractable Diseases Program (grant number: JPMH15FC122).
Publisher Copyright:
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2022
Y1 - 2022
N2 - Objective: Fontan-associated liver disease (FALD) is widely recognised as a common complication in patients long after the Fontan operation. However, data on the predictors of FALD that can guide its screening and management are lacking. The present study aimed to identify the predictors of liver cirrhosis (LC) and hepatocellular carcinoma (HCC) in post-Fontan patients. Methods: This was a multi-institutional retrospective cohort study. Clinical data of all perioperative survivors of Fontan operation before 2011 who underwent postoperative catheterisation were collected through a retrospective chart review. Results: A total of 1117 patients (538 women, 48.2%) underwent their first Fontan operation at a median age of 3.4 years. Postoperative cardiac catheterisation was conducted at a median of 1.0 year. During a median follow-up period of 10.3 years, 67 patients (6.0%) died; 181 (16.2%) were diagnosed with liver fibrosis, 67 (6.0%) with LC, 54 (4.8%) with focal nodular hyperplasia and 7 (0.6%) with HCC. On multivariable analysis, high central venous pressure (CVP) (HR, 1.28 (95% CI 1.01 to 1.63) per 3 mm Hg; p=0.042) and severe atrioventricular valve regurgitation (HR, 6.02 (95% CI 1.53 to 23.77); p=0.010) at the postoperative catheterisation were identified as independent predictors of LC/HCC. Conclusions: Patients with high CVP and/or severe atrioventricular valve regurgitation approximately 1 year after the Fontan operation are at increased risk of developing advanced liver disease in the long term. Whether therapeutic interventions to reduce CVP and atrioventricular valve regurgitation decrease the incidence of advanced liver disease requires further elucidation.
AB - Objective: Fontan-associated liver disease (FALD) is widely recognised as a common complication in patients long after the Fontan operation. However, data on the predictors of FALD that can guide its screening and management are lacking. The present study aimed to identify the predictors of liver cirrhosis (LC) and hepatocellular carcinoma (HCC) in post-Fontan patients. Methods: This was a multi-institutional retrospective cohort study. Clinical data of all perioperative survivors of Fontan operation before 2011 who underwent postoperative catheterisation were collected through a retrospective chart review. Results: A total of 1117 patients (538 women, 48.2%) underwent their first Fontan operation at a median age of 3.4 years. Postoperative cardiac catheterisation was conducted at a median of 1.0 year. During a median follow-up period of 10.3 years, 67 patients (6.0%) died; 181 (16.2%) were diagnosed with liver fibrosis, 67 (6.0%) with LC, 54 (4.8%) with focal nodular hyperplasia and 7 (0.6%) with HCC. On multivariable analysis, high central venous pressure (CVP) (HR, 1.28 (95% CI 1.01 to 1.63) per 3 mm Hg; p=0.042) and severe atrioventricular valve regurgitation (HR, 6.02 (95% CI 1.53 to 23.77); p=0.010) at the postoperative catheterisation were identified as independent predictors of LC/HCC. Conclusions: Patients with high CVP and/or severe atrioventricular valve regurgitation approximately 1 year after the Fontan operation are at increased risk of developing advanced liver disease in the long term. Whether therapeutic interventions to reduce CVP and atrioventricular valve regurgitation decrease the incidence of advanced liver disease requires further elucidation.
KW - cardiac catheterization
KW - fontan procedure
KW - heart defects, congenital
KW - outcome assessment, health care
KW - risk factors
UR - http://www.scopus.com/inward/record.url?scp=85134588873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134588873&partnerID=8YFLogxK
U2 - 10.1136/heartjnl-2022-320940
DO - 10.1136/heartjnl-2022-320940
M3 - Article
C2 - 35768191
AN - SCOPUS:85134588873
SN - 1355-6037
JO - Heart
JF - Heart
M1 - heartjnl-2022-320940
ER -